Business Context and Reporting Period
This Form 8-K is a current report filed by Aileron Therapeutics, Inc. (not Rein Therapeutics, Inc.) on March 25, 2024. The filing addresses significant changes in the company's executive leadership, specifically the departure of the Interim Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation of Susan L. Drexler: Ms. Drexler resigned as Interim Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective March 25, 2024. She will continue to provide consulting services to the company.
- Appointment of Charles Garner: The Board appointed Charles Garner as Principal Financial Officer and Principal Accounting Officer, effective March 25, 2024.
- Planned Departure of Charles Garner: Mr. Garner's employment is scheduled to end on May 15, 2024.
Guidance, Outlook, and Contingencies
Compensatory Arrangements: In connection with his appointment and planned departure, Mr. Garner is entitled to receive twelve (12) months' base salary in the form of severance payments, provided he does not terminate employment without good reason and is not terminated for cause prior to the Separation Date. This includes salary continuation and payment for accrued unused paid time off.
Indemnification: Mr. Garner is expected to enter into the company's standard indemnification agreement, which may require the company to cover certain expenses, including legal fees and judgments, arising from his service as an officer.
Risks and Unusual Items: The filing notes no family relationships between Mr. Garner and other officers/directors and discloses no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the company name is Aileron Therapeutics, Inc. (ALRN), not Rein Therapeutics, Inc.
- Confirm the timeline for the transition of financial leadership between Ms. Drexler and Mr. Garner.
- Review the specific terms of the severance agreement for Mr. Garner, noting the 12-month salary continuation.
- Check for subsequent filings regarding the appointment of a permanent Chief Financial Officer after Mr. Garner's departure on May 15, 2024.